Research
Hormonal
Tirzepatide use can cause drug-induced liver injury (DILI) characterized by elevated transaminases, potentially linked to rapid hepatic fat mobilization.
If you are taking tirzepatide and experience unexplained fatigue or abdominal discomfort, ask your doctor to check liver enzymes (ALT/AST). This liver injury is rare and reversible, but monitoring ensures safety. Do not stop the medication without consulting your provider, as the metabolic benefits are significant.
WeakSupportsLOW confidence
We present a rare case of tirzepatide-induced liver injury in a 37-year-old woman... Tirzepatide was considered a possible cause of the liver injury... diagnosis of drug-induced liver injury (DILI) from tirzepatide was made.
Why this rating
Single case report (n=1), no control group, causality assessed via RUCAM score of 5 (possible).
Source
A Rare Case of Tirzepatide-Induced Hepatotoxicity
Aalam Sohal et al. · ACG Case Reports Journal · 2024
DOI 10.14309/crj.0000000000001484
case_report · n=1Cited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →